Dr. Duarte G. Machado, MD

Dr. Machado practices at Hartford Healthcare Medical Group Specialists in Cheshire, Connecticut.

Dr. Machado's NPI, 1649454976, was assigned on December 21, 2007. Dr. Machado graduated from University of Connecticut School of Medicine in 2005. Dr. Machado holds Connecticut license 047508.

Dr. Machado's primary practice is Hartford Healthcare Medical Group Specialists, at 280 S Main St, Cheshire, CT 06410 in Capitol County. The practice phone is (860) 246-2071.

Dr. Machado's primary practice is Hartford Healthcare Medical Group Specialists in Cheshire, Connecticut. Dr. Machado is also affiliated with Yale New Haven Hospital. The medical group on file is Hartford HealthCare Medical Group Specialists. Dmand AI also links Dr. Machado to 5 more hospitals, 3 group practices and clinics, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Machado practices, 10 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Machado's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Machado is licensed in Connecticut.

CMS data shows 61,851 Medicare services from Dr. Machado across 17 procedure codes in 2024, for 327 Medicare patients. Medicare paid $378,390 for them. Every service was in an office.

CMS counts 327 Medicare patients who saw Dr. Machado in 2024. The largest group is 75 to 84, with 136 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Machado's median patient age at 73, with 51% women.

In 2024, Dr. Machado wrote 6,018 Medicare Part D claims for 685 patients. 73% of them were for generic drugs. CMS names the drug for 5,689 of them, across 96 drugs with 11 or more claims each, at $5,345,527 in total drug cost. In 2023, CMS named 4,905 claims across 81 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Machado for performance year 2024, reported as part of a group. Dr. Machado accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 32 procedures of skin biopsy by Dr. Machado, more than 66% of the clinicians it reports for that procedure.

Dmand AI links 21 papers to Dr. Machado, published from 2011 to 2020. 2017 was the busiest year, with 4. The most frequent topics are Botulinum Toxins, Type A, Double-Blind Method and Neuromuscular Agents. Dr. Machado has published most often in Braz J Anesthesiol. Dr. Machado's most frequent co-authors are Bahman Jabbari, MD, Shivam Om Mittal, MD and Divyanshu Dubey.

CMS Open Payments shows 1,561 general payments to Dr. Machado from 42 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Neurocrine BioSciences, Inc. paid the most, $140,511. It also lists 1 research payment totaling $6,134 in 2023.

Dr. Machado graduated from University of Connecticut School of Medicine in 2005.